Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas

Hiroyuki Orita, Yoshihiko Maehara, Hideaki Anai, Hideo Baba, Hiroki Kusumoto, Daisuke Korenaga, Keizo Sugimachi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalSeminars in Surgical Oncology
Issue number2
Publication statusPublished - 1994

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology


Dive into the research topics of 'Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas'. Together they form a unique fingerprint.

Cite this